Cognition Therapeutics, Inc(CGTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CGTX Cognition Therapeutics, Inc

Not Yet Opened 06-25 16:00:00 EDT

1.13

+0.11

+10.78%

盘后1.11

-0.02-1.78%

19:59 EDT

High1.22	Low0.9300	Vol3.92M
Open1.07	D1 Closing1.02	Amplitude28.43%
Mkt Cap100.97M	Tradable Cap93.26M	Total Shares89.35M
T/O4.22M	T/O Rate4.75%	Tradable Shares82.53M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CGTX","market":"US","secType":"STK","nameCN":"Cognition Therapeutics, Inc","latestPrice":1.13,"timestamp":1782417600000,"preClose":1.02,"halted":0,"volume":3922688,"hourTrading":{"tag":"盘后","latestPrice":1.1099,"preClose":1.13,"latestTime":"19:59 EDT","volume":12180,"amount":13549.5356,"timestamp":1782431987999,"change":-0.0201,"changeRate":-0.017788,"amplitude":0.030796},"delay":0,"changeRate":0.10784313725490184,"floatShares":82532000,"shares":89353773,"eps":-0.245918,"marketStatus":"Not Yet Opened","change":0.11,"latestTime":"06-25 16:00:00 EDT","open":1.07,"high":1.22,"low":0.93,"amount":4216615.01184,"amplitude":0.284314,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.245918,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1782460800000},"marketStatusCode":0,"adr":0,"listingDate":1633665600000,"exchange":"NASDAQ","adjPreClose":1.02,"preHourTrading":{"tag":"盘前","latestPrice":1.07,"preClose":1.02,"latestTime":"09:29 EDT","volume":93820,"amount":99086.49187999999,"timestamp":1782394164670,"change":0.05,"changeRate":0.04902,"amplitude":0.098039},"postHourTrading":{"tag":"盘后","latestPrice":1.1099,"preClose":1.13,"latestTime":"19:59 EDT","volume":12180,"amount":13549.5356,"timestamp":1782431987999,"change":-0.0201,"changeRate":-0.017788,"amplitude":0.030796},"volumeRatio":0.938279},"requestUrl":"/m/hq/s/CGTX/tweets","defaultTab":"tweets","newsList":[{"id":"2646180848","title":"H.C. Wainwright Keeps Their Buy Rating on Cognition Therapeutics (CGTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2646180848","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646180848?lang=en_us&edition=fundamental","pubTime":"2026-06-25 20:36","pubTimestamp":1782390962,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Cognition Therapeutics today and set a price target of $3.00. According to TipRank...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-keeps-their-buy-rating-on-cognition-therapeutics-cgtx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-keeps-their-buy-rating-on-cognition-therapeutics-cgtx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CGTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645908308","title":"Cognition Therapeutics gets FDA feedback on zervimesine study","url":"https://stock-news.laohu8.com/highlight/detail?id=2645908308","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645908308?lang=en_us&edition=fundamental","pubTime":"2026-06-24 19:40","pubTimestamp":1782301214,"startTime":"0","endTime":"0","summary":"Cognition Therapeutics (CGTX) announced that it received written feedback from the FDA following its recent meeting. The FDA agreed that psychosis ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cognition-therapeutics-gets-fda-feedback-on-zervimesine-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cognition-therapeutics-gets-fda-feedback-on-zervimesine-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CGTX","BK4585","BK4588","BK4007","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645897413","title":"Cognition Therapeutics Targets Mid-2027 Start for Phase 3 Zervimesine Trial in DLB Psychosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2645897413","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645897413?lang=en_us&edition=fundamental","pubTime":"2026-06-24 19:30","pubTimestamp":1782300638,"startTime":"0","endTime":"0","summary":"Cognition Therapeutics targets mid-2027 start for Phase 3 zervimesine trial in DLB psychosisCognition Therapeutics received FDA written feedback aligning on key elements of a pivotal Phase 3 study of ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260624:nNDL6QqY0n:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","LU2210150020.SGD","BK4585","IE00BN0W2T93.GBP","SG9999014013.SGD","BK4007","IE00BKPKM429.USD","IE00BN0W2W23.USD","BK4588","SG9999014005.SGD","CGTX","BK4112","IE00B64PRP62.GBP","IE00BN0W2V16.EUR","NDAQ","SG9999014021.USD","IE00BGHQF748.EUR","LU2210149790.SGD","LU0314104364.USD","LU2095319765.USD","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645897906","title":"Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (ct1812) in Dlb Psychosis Following Receipt of FDA Meeting Minutes","url":"https://stock-news.laohu8.com/highlight/detail?id=2645897906","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645897906?lang=en_us&edition=fundamental","pubTime":"2026-06-24 19:30","pubTimestamp":1782300600,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260624:nTUA7YFYFP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CGTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645897464","title":"Cognition Therapeutics - Registrational Program for Zervimesine in Dlb Psychosis to Begin Mid-2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2645897464","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645897464?lang=en_us&edition=fundamental","pubTime":"2026-06-24 19:30","pubTimestamp":1782300600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260624:nTUA7YFYFP:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CGTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645897421","title":"Cognition Therapeutics - to Use Neuropsychiatric Inventory as Primary Endpoint in Pivotal Dlb Psychosis Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2645897421","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645897421?lang=en_us&edition=fundamental","pubTime":"2026-06-24 19:30","pubTimestamp":1782300600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260624:nTUA7YFYFP:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CGTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645026440","title":"H.C. Wainwright Reaffirms Their Buy Rating on Cognition Therapeutics (CGTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2645026440","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645026440?lang=en_us&edition=fundamental","pubTime":"2026-06-22 18:39","pubTimestamp":1782124779,"startTime":"0","endTime":"0","summary":"In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Cognition Therapeutics, with a price target of $3.00. Sel...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-reaffirms-their-buy-rating-on-cognition-therapeutics-cgtx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-reaffirms-their-buy-rating-on-cognition-therapeutics-cgtx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CGTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644859540","title":"Cognition Therapeutics Shareholders Elect Directors, Ratify Auditor","url":"https://stock-news.laohu8.com/highlight/detail?id=2644859540","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644859540?lang=en_us&edition=fundamental","pubTime":"2026-06-18 20:33","pubTimestamp":1781785995,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Cognition Therapeutics ( ($CGTX) ). On June 17, 2026, Cognition Therapeutics, Inc. held its Annual Meeting of S...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cognition-therapeutics-shareholders-elect-directors-ratify-auditor?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cognition-therapeutics-shareholders-elect-directors-ratify-auditor?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CGTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644083676","title":"Cognition Therapeutics shareholders elect Aaron Fletcher, Lisa Ricciardi as Class II directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2644083676","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644083676?lang=en_us&edition=fundamental","pubTime":"2026-06-18 20:06","pubTimestamp":1781784364,"startTime":"0","endTime":"0","summary":"Cognition Therapeutics held its annual shareholder meeting on June 17, 2026.Stockholders backed the selection of Aaron Fletcher, Ph.D., Lisa Ricciardi as Class II directors with terms running to the 2029 annual meeting.Ernst & Young was ratified as independent registered public accounting firm for fiscal 2026; the vote authorizes the appointment, not audit execution.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cognition Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 18, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260618:nNDL1qxfW2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CGTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643475252","title":"Cognition Therapeutics Receives Patent Allowance for Polymorphic Crystalline Form of Zervimesine","url":"https://stock-news.laohu8.com/highlight/detail?id=2643475252","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643475252?lang=en_us&edition=fundamental","pubTime":"2026-06-16 20:19","pubTimestamp":1781612362,"startTime":"0","endTime":"0","summary":"Cognition Therapeutics  said Tuesday it has received a notice of allowance from the US Patent and Trademark Office for its patent application covering a polymorphic crystalline form of zervimesine, its lead drug candidate for Alzheimer's disease.The patent, once issued, will provide protection for the formulation through 2045 and, if granted a standard five-year extension, through 2050, the company said.The formulation is a potential treatment for age-related degenerative disorders such as Alzheimer's disease, geographic atrophy, and dementia with Lewy bodies, the company said.The latest configuration of this polymorphic form of zervimesine has a better pharmaceutical profile with greater chemical stability, Cognition said.Shares of the company were up 2.5% in premarket activity Tuesday.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","CGTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643751297","title":"Cognition Therapeutics says USPTO allows zervimesine patent application extending protection to 2045","url":"https://stock-news.laohu8.com/highlight/detail?id=2643751297","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643751297?lang=en_us&edition=fundamental","pubTime":"2026-06-16 19:31","pubTimestamp":1781609476,"startTime":"0","endTime":"0","summary":"Cognition Therapeutics received a USPTO Notice of Allowance for a composition-of-matter patent application covering a crystalline form of zervimesine .Once issued, the patent would extend U.S. protection for the lead candidate through 2045, with a potential 5-year extension to 2050.The application also covers a proprietary manufacturing process, with the company planning to use the new form in registrational trials for DLB psychosis.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nNDL9zXbdB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","SG9999014013.SGD","LU2095319765.USD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","CGTX","LU2210150020.SGD","SG9999014005.SGD","IE00BGHQF748.EUR","LU0314104364.USD","BK4112","NDAQ","IE00BN0W2V16.EUR","IE00BKPKM429.USD","LU2210149790.SGD","BK4588","IE00BN0W2W23.USD","SG9999014021.USD","SG9999014039.USD","BK4585","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643510397","title":"Cognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) Through 2045","url":"https://stock-news.laohu8.com/highlight/detail?id=2643510397","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643510397?lang=en_us&edition=fundamental","pubTime":"2026-06-16 19:30","pubTimestamp":1781609400,"startTime":"0","endTime":"0","summary":"PURCHASE, N.Y., June  16, 2026  (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/16/3312453/0/en/Cognition-Therapeutics-Announces-New-Composition-of-Matter-Patent-Extending-Patent-Protection-for-Lead-Candidate-Zervimesine-CT1812-Through-2045.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0205193047.USD","DBB","DLB","LU0205194284.USD","LU0240877869.USD","LU0345774631.USD","LU0348723411.USD","CGTX","LU0345774391.USD","BK4097","BK4007","LU0240878834.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642435762","title":"Cognition Therapeutics (CGTX) Gets a Buy from H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2642435762","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642435762?lang=en_us&edition=fundamental","pubTime":"2026-06-09 01:35","pubTimestamp":1780940130,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Cognition Therapeutics today and set a price target of $3.00. According to TipRank...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/cognition-therapeutics-cgtx-gets-a-buy-from-h-c-wainwright-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/cognition-therapeutics-cgtx-gets-a-buy-from-h-c-wainwright-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","CGTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640157019","title":"Cognition Therapeutics Advances Zervimesine Toward Phase 3 DLB Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2640157019","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640157019?lang=en_us&edition=fundamental","pubTime":"2026-06-04 20:34","pubTimestamp":1780576443,"startTime":"0","endTime":"0","summary":"Cognition Therapeutics ( ($CGTX) ) has issued an announcement. Cognition Therapeutics has furnished an investor presentation outlining the advancem...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cognition-therapeutics-advances-zervimesine-toward-phase-3-dlb-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cognition-therapeutics-advances-zervimesine-toward-phase-3-dlb-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CGTX","LU0205194284.USD","LU0345774631.USD","LU0205193047.USD","DLB","BK4007","BK4097","LU0240877869.USD","LU0240878834.USD","LU0348723411.USD","LU0345774391.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640562439","title":"Cognition Therapeutics CEO presents at Jefferies Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2640562439","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640562439?lang=en_us&edition=fundamental","pubTime":"2026-06-01 19:33","pubTimestamp":1780313626,"startTime":"0","endTime":"0","summary":"Cognition Therapeutics will present at the 2026 Jefferies Global Healthcare Conference on June 4, 2026 at 1:25 p.m. ET.Lisa Ricciardi is set to give updates on plans for a registrational program in dementia with Lewy bodies psychosis.The company will also present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit, available on-demand from June 15, 2026 at 8:00 a.m. ET.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDLbJ7JCs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","BK4007","LU2095319765.USD","IE00BN0W2W23.USD","LU2210149790.SGD","SG9999014013.SGD","IE00BN0W2V16.EUR","BK4588","BK4112","BK4585","LU0314104364.USD","IE00B3QW5Z07.USD","CGTX","LU2210150020.SGD","IE00BKPKM429.USD","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","SG9999014021.USD","NDAQ","SG9999014039.USD","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640795933","title":"Cognition Therapeutics Participating in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2640795933","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640795933?lang=en_us&edition=fundamental","pubTime":"2026-06-01 19:30","pubTimestamp":1780313400,"startTime":"0","endTime":"0","summary":"PURCHASE, N.Y., June  01, 2026  (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the Co","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/01/3304237/0/en/Cognition-Therapeutics-Participating-in-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0205194284.USD","LU0345774631.USD","DLB","LU0240877869.USD","LU0205193047.USD","LU0240878834.USD","LU0345774391.USD","CGTX","LU0348723411.USD","BK4007","BK4097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638651080","title":"Peter Thiel-Backed AI Coding Startup Cognition Hits $26 Billion Valuation","url":"https://stock-news.laohu8.com/highlight/detail?id=2638651080","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638651080?lang=en_us&edition=fundamental","pubTime":"2026-05-28 12:37","pubTimestamp":1779943020,"startTime":"0","endTime":"0","summary":"Artificial-intelligence coding startup Cognition has raised more than $1 billion in a new funding round that brings its valuation to $26 billion.The round was led by Lux Capital, General Catalyst, and 8VC, the company said late Wednesday. Existing investors that participated included Peter Thiel's Founders Fund and Bain Capital Ventures.Cognition's valuation, after including the funds raised, has more than doubled from its prior funding round in September.San Francisco-based Cognition describes its flagship product, Devin, as an \"AI software engineer,\" referring to the tool's ability to write computer code autonomously. Devin was launched two years ago.The company said the new funding will be used to expand research and engineering, scale enterprise deployments, invest in infrastructure and continue international expansion.Cognition has over 250 employees worldwide, and launched international offices in Tokyo, Japan and Singapore earlier this year. It counts U.S. federal agencies and b","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0048573561.USD","BK4504","LU1894683264.USD","LU2471134796.USD","LU0868494708.USD","BK4598","BK4535","LU2471134879.HKD","LU1804176565.USD","PLTG","PLTY","LU1861220207.SGD","BK4106","LU1861559042.SGD","IE00BSNM7G36.USD","LU2237443895.HKD","LU2750360997.AUD","BK4588","LU2237443622.USD","PLTR","PLTU","GS","BK4547","BK4527","BK4552","IE00B19Z3581.USD","IE00BQXX3F31.USD","LU2237443978.SGD","PYPY","LU1868837300.USD","LU1868836757.USD","LU2237443465.HKD","BK4533","LU0096364046.USD","LU2237438978.USD","LU2237443382.USD","LU1668664300.SGD","PLTD","LU0158827948.USD","LU2471134952.CNY","IE00BFXG1179.USD","LU2471134523.USD","PLTZ","BK4543","PLTW","BK4585","BK4613","IE0002270589.USD","LU2237443549.SGD","PYPL","PLT","PLTI","LU1791807156.HKD","BK4516","IE00B19Z3B42.SGD","BK4534","IE0034235188.USD","IE0004086264.USD","IE00B19Z9Z06.USD","PLYY","PTIR","LU1861217088.USD","LU0345770308.USD","IE00BQXX3D17.EUR","IE00BZ9MQY76.HKD","BK4551","LU1868837136.USD","LU0061475181.USD","PLOO","PLTA","IE00B894F039.SGD","LU0742534661.SGD","LU2360107671.USD","LU0345770993.USD","IE0004091025.USD","LU1861558580.USD","LU2023251221.USD","LU0868494617.USD","CGTX","BK4550","LU0251131958.USD","GSX","PYPG","BK4554","LU2265009873.SGD","IE00B19Z9P08.USD","LU0942090050.USD","BK4007","LU0106831901.USD","LU1868836591.USD","BK4023","BK4566","BK4581","LU0251142724.SGD","LU1894683348.USD","BK4524","LU1868836914.USD","LU2089283258.USD","LU2750360641.GBP","LU2089284900.SGD","IE00BQXX3C00.GBP","BK4127","BK4227"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638572504","title":"KDventures Portfolio Firm Highlights Severe Fatigue as Key Unmet Need in PBC","url":"https://stock-news.laohu8.com/highlight/detail?id=2638572504","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638572504?lang=en_us&edition=fundamental","pubTime":"2026-05-27 15:12","pubTimestamp":1779865968,"startTime":"0","endTime":"0","summary":"KDventures AB ( ($SE:KDV.B) ) has issued an update. KDventures’ portfolio company Umecrine Cognition has reported new survey data from 250 adults w...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kdventures-portfolio-firm-highlights-severe-fatigue-as-key-unmet-need-in-pbc?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kdventures-portfolio-firm-highlights-severe-fatigue-as-key-unmet-need-in-pbc?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","CGTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637333736","title":"Cognition Therapeutics Advances Zervimesine Toward Late-Stage DLB Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2637333736","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637333736?lang=en_us&edition=fundamental","pubTime":"2026-05-21 19:58","pubTimestamp":1779364681,"startTime":"0","endTime":"0","summary":"Cognition Therapeutics ( ($CGTX) ) has provided an announcement. On May 20, 2026, Cognition Therapeutics held a planned meeting with the U.S. Food ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cognition-therapeutics-advances-zervimesine-toward-late-stage-dlb-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cognition-therapeutics-advances-zervimesine-toward-late-stage-dlb-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4097","LU0205193047.USD","BK4007","LU0348723411.USD","LU0345774631.USD","DLB","SSI","LU0240878834.USD","LU0345774391.USD","CGTX","LU0205194284.USD","LU0240877869.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637333814","title":"Cognition Therapeutics plans late-stage zervimesine trial for Lewy body dementia psychosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2637333814","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637333814?lang=en_us&edition=fundamental","pubTime":"2026-05-21 19:30","pubTimestamp":1779363037,"startTime":"0","endTime":"0","summary":"Cognition Therapeutics met the FDA on May 20, 2026 to review Phase 2 results for zervimesine  in dementia with Lewy bodies patients with psychosis, outlining a proposed registrational study.The discussion was described as positive, supporting a path forward to move the drug into a late-stage program for this indication.Formal FDA meeting minutes are expected in June, setting up the next decision point for the registrational trial design and endpoints.The company also noted zervimesine is being studied in the Phase 2 START trial in mild cognitive impairment and early Alzheimer’s disease.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nNDL9SKnC8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","IE00BKPKM429.USD","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","BK4588","NDAQ","LU2095319765.USD","LU2210150020.SGD","BK4007","IE00BN0W2W23.USD","SG9999014005.SGD","CGTX","SG9999014021.USD","BK4585","SG9999014013.SGD","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","LU0314104364.USD","LU2210149790.SGD","IE00BGHQF748.EUR","BK4112"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cogrx.com","stockEarnings":[{"period":"1week","weight":-0.2207},{"period":"1month","weight":-0.0887},{"period":"3month","weight":0.5477},{"period":"6month","weight":-0.2207},{"period":"1year","weight":2.7667},{"period":"ytd","weight":-0.163}],"compareEarnings":[{"period":"1week","weight":-0.0167},{"period":"1month","weight":-0.0217},{"period":"3month","weight":0.158},{"period":"6month","weight":0.0637},{"period":"1year","weight":0.2095},{"period":"ytd","weight":0.0768}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.060065},{"month":2,"riseRate":0,"avgChangeRate":-0.189802},{"month":3,"riseRate":0.2,"avgChangeRate":-0.073136},{"month":4,"riseRate":0.8,"avgChangeRate":0.125839},{"month":5,"riseRate":0.4,"avgChangeRate":-0.077033},{"month":6,"riseRate":0.2,"avgChangeRate":-0.039366},{"month":7,"riseRate":0.25,"avgChangeRate":0.074037},{"month":8,"riseRate":0.5,"avgChangeRate":0.719491},{"month":9,"riseRate":0,"avgChangeRate":-0.232471},{"month":10,"riseRate":0.5,"avgChangeRate":0.012004},{"month":11,"riseRate":0.2,"avgChangeRate":0.100902},{"month":12,"riseRate":0.4,"avgChangeRate":0.102692}],"exchange":"NASDAQ","name":"Cognition Therapeutics, Inc","nameEN":"Cognition Therapeutics, Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Cognition Therapeutics, Inc(CGTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Cognition Therapeutics, Inc(CGTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Cognition Therapeutics, Inc,CGTX,Cognition Therapeutics, Inc股票,Cognition Therapeutics, Inc股票老虎,Cognition Therapeutics, Inc股票老虎国际,Cognition Therapeutics, Inc行情,Cognition Therapeutics, Inc股票行情,Cognition Therapeutics, Inc股价,Cognition Therapeutics, Inc股市,Cognition Therapeutics, Inc股票价格,Cognition Therapeutics, Inc股票交易,Cognition Therapeutics, Inc股票购买,Cognition Therapeutics, Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Cognition Therapeutics, Inc(CGTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Cognition Therapeutics, Inc(CGTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction